Our Vision
Redefining What’s Drug-Accessible
Our vision is to make cytosolic delivery a solved problem — enabling the next generation of precision oncology therapies.
SCROLL
The Opportunity
Most High-Value Targets Are Inside the Cell
Many of the most important oncology targets remain difficult to drug because therapeutic payloads cannot reliably reach the cytosol. Solving that barrier has the potential to expand the range of treatable targets and therapeutic approaches.
The Cytosolic Delivery Problem
Oncology drug discovery continues to identify proteins to degrade, silence, or inhibit. But many of these programs fail to translate because the therapeutic does not reliably reach its intracellular site of action. XELCIS XB is designed to close that gap.
Our Approach
Delivery as Foundational Infrastructure
Rather than building a single-product company, Xelcis is building a delivery platform designed to support multiple modalities, targets, and partner programs.
Platform Over Product
A single enabling technology with leverage across the oncology landscape. Each validated modality expands the platform’s reach.
Designed for Partnership
XELCIS XB is built to integrate into partner programs by adding delivery capability to assets already in development.
Capital-Efficient by Design
A licensing and collaboration model allows partners to validate their own targets while expanding the platform data set and commercial opportunity.
Precision Delivery
Engineered for Cytosolic Delivery
XELCIS XB is designed to overcome endosomal entrapment and deliver payloads to the cytosol with selectivity and functional relevance.
Long-Term Vision
A Platform for the Next Generation of Oncology
If cytosolic delivery can be made reliable and scalable, the impact extends far beyond any single program.
Enable Previously Inaccessible Targets
Targets long considered difficult to drug may become actionable when cytosolic delivery is solved.
Improve Success Rates Across Therapeutic Classes
By addressing a core cause of failure, XELCIS XB has the potential to improve success rates across multiple oncology modalities.
Foundational Delivery Technology for Partners
Like GalNAc in RNA therapeutics, XELCIS XB aims to become enabling delivery infrastructure for oncology programs that depend on cytosolic access.
